Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4532990 dose-finding placebo-controlled study in alcohol-related steatohepatitis
2024-511596-15-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Oct 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in alcoholic liver disease (ALD) and steatohepatitis comparing GSK4532990 with Placebo (2 arms). Primary endpoints: Change from baseline in liver stiffness measurement and Change from baseline in MELD score. Planned start Oct 2024; status: authorised.
02
Drugs
GSK4532990
03
Conditions
alcoholic liver disease (ALD)steatohepatitis
Beyond the preview
Go deeper on 2024-511596-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511596-15-00.